Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Piotr Rutkowski

Showing results (211-220 of 491) with videos related to

Pageof 50
Sort By:
Postepy Dermatologii I Alergologii|January 23, 2023
Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapiesMarcin Ziętek, Marcin Zdzienicki, Jędrzej Wierzbicki, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2014
Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapyLydia Lartigue, Agnès Neuville, Pauline Lagarde, et al.
Genes|May 27, 2026
Detection of Gene Fusions in Soft Tissue Sarcoma Using Next-Generation SequencingPiotr Remiszewski, Klaudia Bobak, Jakub Piątkowski, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2016
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivityAlexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Cancers|December 10, 2021
Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" TrialChe-Jui Lee, Elodie Modave, Bram Boeckx, et al.
Cancers|March 10, 2022
Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with MelanomaAnna Dawidowska, Paulina Jagodzinska-Mucha, Hanna Koseła-Paterczyk, et al.
Journal of Clinical Medicine|August 10, 2024
Minimally Invasive Plasma Device Management of Multiple Benign Skin Cancers Associated with Rare Genodermatoses-Case Series and Review of the Therapeutic MethodsAnna Płatkowska, Monika Słowińska, Joanna Zalewska, et al.
Medical Oncology (Northwood, London, England)|February 4, 2012
Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patientsSergiusz Markowicz, Zbigniew I Nowecki, Piotr Rutkowski, et al.
Journal of Applied Genetics|December 18, 2025
Clinicopathological and genomic profiling in undifferentiated pleomorphic sarcoma: Small series, clear messagePiotr Remiszewski, Andrzej Tysarowski, Katarzyna A Seliga, et al.
Clinical Chemistry|August 21, 2003
Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanomaJolanta Szenajch, Bogdan Jasiński, Agnieszka Synowiec, et al.
Pageof 50

Showing results (211-220 of 491) with videos related to

Sort By:
Pageof 50
Postepy Dermatologii I Alergologii|January 23, 2023
Survival of patients with stage IIIC and IIID melanomas with nodal metastases in the light of new therapiesMarcin Ziętek, Marcin Zdzienicki, Jędrzej Wierzbicki, et al.
European Journal of Cancer (Oxford, England : 1990)|December 4, 2014
Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapyLydia Lartigue, Agnès Neuville, Pauline Lagarde, et al.
Genes|May 27, 2026
Detection of Gene Fusions in Soft Tissue Sarcoma Using Next-Generation SequencingPiotr Remiszewski, Klaudia Bobak, Jakub Piątkowski, et al.
European Journal of Cancer (Oxford, England : 1990)|January 21, 2016
Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivityAlexander M M Eggermont, Stefan Suciu, Piotr Rutkowski, et al.
Cancers|December 10, 2021
Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 "CREATE" TrialChe-Jui Lee, Elodie Modave, Bram Boeckx, et al.
Cancers|March 10, 2022
Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with MelanomaAnna Dawidowska, Paulina Jagodzinska-Mucha, Hanna Koseła-Paterczyk, et al.
Journal of Clinical Medicine|August 10, 2024
Minimally Invasive Plasma Device Management of Multiple Benign Skin Cancers Associated with Rare Genodermatoses-Case Series and Review of the Therapeutic MethodsAnna Płatkowska, Monika Słowińska, Joanna Zalewska, et al.
Medical Oncology (Northwood, London, England)|February 4, 2012
Adjuvant vaccination with melanoma antigen-pulsed dendritic cells in stage III melanoma patientsSergiusz Markowicz, Zbigniew I Nowecki, Piotr Rutkowski, et al.
Journal of Applied Genetics|December 18, 2025
Clinicopathological and genomic profiling in undifferentiated pleomorphic sarcoma: Small series, clear messagePiotr Remiszewski, Andrzej Tysarowski, Katarzyna A Seliga, et al.
Clinical Chemistry|August 21, 2003
Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanomaJolanta Szenajch, Bogdan Jasiński, Agnieszka Synowiec, et al.
Pageof 50